In:
Interventional Cardiology Review, Radcliffe Media Media Ltd, Vol. 10, No. 2 ( 2015), p. 109-
Abstract:
Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF). Recently, the Watchman device (Boston Scientific, St Paul, MN, US) was approved in the US by the Food and Drug Administration (FDA) based on the results of two randomised clinical trials that evaluated LAAO in patients eligible for oral anticoagulation (OAC) therapy. However, in real-word clinical practice LAAO is typically offered to patients ineligible for OAC therapy, as they appear to have limited treatment options and consequently worse prognosis. Although LAAO has shown favourable clinical outcomes in OAC-ineligible patients in single or multicentre observational studies, these results need to be confirmed in randomised clinical trials.
Type of Medium:
Online Resource
ISSN:
1756-1477
DOI:
10.15420/icr.2015.10.2.109
Language:
English
Publisher:
Radcliffe Media Media Ltd
Publication Date:
2015
detail.hit.zdb_id:
2813989-6
Permalink